Business
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in France. According to the latest data collected by the European Cancer Information System (click here), a total of 66,328 new cases of breast cancer were diagnosed in France in 2022, which is the most common cancer diagnosed in women, representing approximately 33% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in France with 14,739 deaths in 2022. The Company has partnered with Unicancer and its breast cancer group (UCBG), the largest academic breast cancer research network in France. The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by French authorities in Q1 2024, which led to site initiation visits and training of 15 sites in Q2-Q4 of 2024, with the remaining 4 sites scheduled for start-up activities in Q1-Q2 of 2025. Unicancer is the only hospital network in France entirely dedicated to the fight against cancer and the only national hospital federation dedicated to oncology. It brings together 18 Cancer Centers (CLCC), non-profit private healthcare institutions, spread across 20 hospital sites in France, along with two affiliated member institutions. The CLCCs care for nearly 530,000 patients annually (in short-stay, home hospitalization, and outpatient care). Unicancer is also the leading academic sponsor of clinical trials in oncology on a European scale, with 106 active clinical trials sponsored in 2020 and nearly 7,600 patients enrolled. Unicancer also leads flagship programs that enable the use of real-world data to improve the understanding and evaluation of therapeutic strategies, particularly through the ESME platforms, which gather data from over 76,000 cancer patients. Recognized as a leader in research in France, the Unicancer network enjoys a global reputation, contributing to a third of the internationally significant French publications in oncology (source: bibliometric study/Thomson Reuters). In total, nearly 700 clinical trials (enrollment or follow-up) we...